(Q36150854)

12 August 2017

1 reference

title

Src kinases as targets for B cell acute lymphoblastic leukaemia therapy (English)

1 reference

12 August 2017

1 reference

Shaoguang Li

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Therapeutic Targets

12 August 2017

published in

1 reference

12 August 2017

volume

9

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

329-341

1 reference

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

p53 in chronic myelogenous leukemia in acute phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR-ABL down-regulates the DNA repair protein DNA-PKcs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The LCK gene is involved in the t(1;7)(p34;q34) in the T-cell acute lymphoblastic leukemia derived cell line, HSB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Thymic tumorigenesis induced by overexpression of p56lck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Model mice for BCR/ABL-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Regulation of the Fas apoptotic cell death pathway by Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Regulation of Btk function by a major autophosphorylation site within the SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Critical role for Gab2 in transformation by BCR/ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

A role for Wnt signalling in self-renewal of haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Wnt proteins are lipid-modified and can act as stem cell growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Target cell in chronic myeloid leukaemia and its relationship to acute lymphoid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.329

21 January 2018

Identifiers

DOI

10.1517/14728222.9.2.329

1 reference

12 August 2017

1 reference